FGFR3-Specific Inhibitor Makes a Strong Debut

LY3866288, an FGR3-specific inhibitor, led to an objective response in 42% of patients with metastatic urothelial carcinoma in a phase I study. The drug did not induce adverse events more commonly seen with erdafitinib, a drug typically used to treat the disease that targets all four FGFR isoforms.